Author:
Burden A. M.,Tadrous M.,Calzavara A.,Cadarette S. M.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Reference24 articles.
1. Aclasta receives Health Canada approval as once-yearly treatment for postmenopausal osteoporosis. November 6th, 2007. http://www.firstwordpharma.com/node/79998?tsid=17#axzz35a6Vb8bz
2. Prolia (denosumab) approved by Health Canada for the treatment of postmenopausal women with osteoporosis at high risk for fracture. September 8, 2010. In: Amgen. http://www.amgen.ca/english/media/treatment_of_postmenopausal.html
3. Women in Ontario now have access to Prolia (denosumab) for postmenopausal osteoporosis. February 29, 2012. http://www.newswire.ca/en/story/929571/women-in-ontario-now-have-access-to-prolia-denosumab-for-postmenopausal-osteoporosis
4. Gamble J-M, McAlister FA, Johnson JA, Eurich DT (2012) Restrictive drug coverage policies can induce substantial drug exposure misclassification in pharmacoepidemiologic studies. Clin Ther 34:1379–1386. doi: 10.1016/j.clinthera.2012.04.009 , e3
5. Schneeweiss S, Gagne JJ, Glynn RJ et al (2011) Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 90:777–790. doi: 10.1038/clpt.2011.235
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献